Safety, tolerability, and pharmacokinetic profile of dabrafenib in Japanese patients with BRAF

Authors :: Yutaka, Fujiwara
Naoya, Yamazaki
Yoshio, Kiyohara
Shusuke, Yoshikawa
Noboru, Yamamoto
Arata, Tsutsumida
Hiroshi, Nokihara
Kenjiro, Namikawa
Akihira, Mukaiyama
Fanghong, Zhang
Tomohide, Tamura
Source :: Investigational new drugs. 36(2)
Publication Year :: 2017
Abstract: Background Dabrafenib is a BRAF inhibitor that has demonstrated clinical activity with a good tolerability profile in patients with BRAF

Subjects :: Adult
Male
Proto-Oncogene Proteins B-raf
Treatment Outcome
Asian People
Dose-Response Relationship, Drug
Neoplasms
Mutation
Oximes
Imidazoles
Humans
Female
Middle Aged

Tools